![]()
|
|
||||||||
J. Biol. Chem., Vol. 276, Issue 20, 17420-17428, May 18, 2001
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Intrinsic expression of the multidrug resistance
(MDR) transporter P-glycoprotein (Pgp) may be regulated by reactive
oxygen species (ROS). A transient expression of Pgp was observed during the growth of multicellular tumor spheroids. Maximum Pgp expression occurred in tumor spheroids with a high percentage of quiescent, Ki-67-negative cells, elevated glutathione levels, increased expression of the cyclin-dependent kinase inhibitors
p27Kip1 and p21WAF-1 as well as reduced
ROS levels and minor activity of the mitogen-activated kinase (MAPK)
members c-Jun amino-terminal kinase (JNK), extracellular signal-regulated kinase ERK1,2, and p38 MAPK. Raising intracellular ROS
by depletion of glutathione with buthionine sulfoximine (BSO) or
glutamine starvation resulted in down-regulation of Pgp and p27Kip1, whereas ERK1,2 and JNK were activated.
Down-regulation of Pgp was furthermore observed with low concentrations
of hydrogen peroxide and epidermal growth factor, indicating that ROS
may regulate Pgp expression. The down-regulation of Pgp following BSO
treatment was abolished by agents interfering with receptor tyrosine
kinase signaling pathways, i.e. the protein kinase C
inhibitors bisindolylmaleimide I (BIM-1) and Ro-31-8220, the
p21ras farnesyl protein transferase inhibitor III, the
c-Raf inhibitor ZM 336372 and PD98059, which inhibits ERK1,2
activation. ROS involved as second messengers in receptor tyrosine
kinase signaling pathways may act as negative regulators of Pgp expression.
Down-regulation of Intrinsic P-glycoprotein Expression
in Multicellular Prostate Tumor Spheroids by Reactive Oxygen
Species*
,
,
,
,
, and
¶
Department of Neurophysiology and the
§ Department III for Internal Medicine, University of
Cologne, D-50931 Cologne, Germany
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
This article has been cited by other articles:
![]() |
R. Callaghan, E. Crowley, S. Potter, and I. D. Kerr P-glycoprotein: So Many Ways to Turn It On J. Clin. Pharmacol., March 1, 2008; 48(3): 365 - 378. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zhou, M. Liu, R. Aneja, R. Chandra, H. Lage, and H. C. Joshi Reversal of P-glycoprotein-Mediated Multidrug Resistance in Cancer Cells by the c-Jun NH2-Terminal Kinase Cancer Res., January 1, 2006; 66(1): 445 - 452. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z.-H. Miao and J. Ding Transcription Factor c-Jun Activation Represses mdr-1 Gene Expression Cancer Res., August 1, 2003; 63(15): 4527 - 4532. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |